0000929638-23-002987.txt : 20231102
0000929638-23-002987.hdr.sgml : 20231102
20231102160859
ACCESSION NUMBER: 0000929638-23-002987
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231031
FILED AS OF DATE: 20231102
DATE AS OF CHANGE: 20231102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Glickman Richard M
CENTRAL INDEX KEY: 0001352637
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41854
FILM NUMBER: 231372331
MAIL ADDRESS:
STREET 1: C/O ASPREVA PHARMACEUTICALS CORPORATION
STREET 2: 1203-4464 MARKHAM STREET
CITY: VICTORIA
STATE: A1
ZIP: V8Z7X8
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: enGene Holdings Inc.
CENTRAL INDEX KEY: 0001980845
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1031
BUSINESS ADDRESS:
STREET 1: 7171 RUE FREDERICK BANTING
CITY: SAINT-LAURENT
STATE: A8
ZIP: H4S 1Z9
BUSINESS PHONE: (514) 332-4888
MAIL ADDRESS:
STREET 1: 7171 RUE FREDERICK BANTING
CITY: SAINT-LAURENT
STATE: A8
ZIP: H4S 1Z9
4
1
form4.xml
X0508
4
2023-10-31
0001980845
enGene Holdings Inc.
ENGN
0001352637
Glickman Richard M
C/O 7171 RUE FREDERICK BANTING
SAINT-LAURENT
A8
H4S 1Z9
QUEBEC, CANADA
true
false
Common Shares
2023-10-31
4
A
0
24555
A
24555
D
Stock Option (Right to Buy)
0.88
2013-12-04
4
A
0
120
A
2023-12-04
Common Shares
120
120
D
Stock Option (Right to Buy)
0.88
2015-05-21
4
A
0
11189
A
2025-05-21
Common Shares
11189
11189
D
Stock Option (Right to Buy)
0.88
2016-01-11
4
A
0
9023
A
2026-01-11
Common Shares
9023
9023
D
Stock Option (Right to Buy)
0.88
2017-06-15
4
A
0
3188
A
2027-06-15
Common Shares
3188
3188
D
Stock Option (Right to Buy)
0.88
2018-03-16
4
A
0
4123
A
2028-03-16
Common Shares
4123
4123
D
Stock Option (Right to Buy)
0.88
2020-12-14
4
A
0
12032
A
2030-12-14
Common Shares
12032
12032
D
Stock Option (Right to Buy)
0.88
2021-08-20
4
A
0
14205
A
2031-08-20
Common Shares
14205
14205
D
Stock Option (Right to Buy)
0.88
2021-08-20
4
A
0
12001
A
2031-08-20
Common Shares
12001
12001
D
On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".
Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.
Reflects Common Shares acquired pursuant to the Business Combination.
This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 667 common shares of enGene.
This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 62,000 common shares of enGene.
This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 50,000 common shares of enGene.
This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 17,668 common shares of enGene.
This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 22,848 common shares of enGene.
This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,667 common shares of enGene.
This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 78,712 common shares of enGene.
This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,500 common shares of enGene.
/s/ Richard Glickman
2023-11-02